Publications

Journey of the tuberculosis patients in India from onset of symptom till one-year post-treatment.

Chatterjee, S; Das, P; Shikhule, A; Munje, R; VASSALL, A;

2023

PLOS global public health, (2023).3 2 10.1371/journal.pgph.0001564.

Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.

Choi, HC W; Leung, K; Chan, KK L; Bai, Y; JIT, M; Wu, JT;

2023

BMC medicine, (2023).21, 10.1186/s12916-023-02748-3.

yangclaraliu/covid_vac_africa: BMCMed_R3.

LIU, Y; PROCTER, SR; PEARSON, CA B; MADRIZ MONTERO, A; TORRES-RUEDA, S; Asfaw, E; Uzochukwu, B; Drake, T; Bergren, E; EGGO, RM; Ruiz, F; Ndembi, N; Nonvignon, J; JIT, M; VASSALL, A;

2023

, Zenodo (2023).

Too much of nothing: measuring, understanding and explaining the overprovision of healthcare in the Tanzanian private sector.

KING, J;

2023

(2023). 10.17037/PUBS.04670819.

Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.

Getaneh, AM; Li, X; Mao, Z; Johannesen, CK; Barbieri, E; Van Summeren, J; Wang, X; Tong, S; Baraldi, E; Phijffer, E; Rizzo, C; Van Wijhe, M; Heikkinen, T; Bont, L; Willem, L; JIT, M; Beutels, P; Bilcke, J; For Respiratory Syncytial Virus Consortium in Euro,;

2023

Vaccine, (2023).41 9 10.1016/j.vaccine.2023.01.058.

Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective.

Chalet, F-X; Bujaroska, T; Germeni, E; Ghandri, N; Maddalena, ET; Modi, K; Olopoenia, A; Thompson, J; Togninalli, M; BRIGGS, AH;

2023

PharmacoEconomics - open, (2023).7 1 10.1007/s41669-023-00388-0.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.

Portnoy, A; CLARK, RA; Quaife, M; WEERASURIYA, CK; Mukandavire, C; Bakker, R; Deol, AK; Malhotra, S; Gebreselassie, N; Zignol, M; Sim, SY; Hutubessy, RC W; Baena, IG; Nishikiori, N; JIT, M; WHITE, RG; Menzies, NA;

2023

PLOS Medicine, (2023).20 1 10.1371/journal.pmed.1004155.

Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.

Cheng, Q; Cunningham, EB; Shih, S; Amin, J; Bruneau, J; Artenie, AA; Powis, J; Litwin, AH; Cooper, C; Dalgard, O; Hellard, M; Bruggmann, P; Marks, P; Lacombe, K; Stedman, C; Read, P; Hajarizadeh, B; Dunlop, AJ; Conway, B; Feld, JJ; Dore, GJ; Grebely, J; SIMPLIFY and D3FEAT Study Groups,;

2023

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, (2023).26 6 10.1016/j.jval.2022.12.016.

Improving economic evaluation and decision-making for oncology drugs using real-world data.

KANG, J;

2023

(2023). 10.17037/PUBS.04670689.

Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.

Smith, J; Bansi-Matharu, L; Cambiano, V; Dimitrov, D; Bershteyn, A; Van de Vijver, D; Kripke, K; Revill, P; Boily, M-C; Meyer-Rath, G; Taramusi, I; Lundgren, JD; Van Oosterhout, JJ; Kuritzkes, D; Schaefer, R; Siedner, MJ; Schapiro, J; Delany-Moretlwe, S; Landovitz, RJ; Flexner, C; Jordan, M; Venter, F; Radebe, M; Ripin, D; Jenkins, S; ... HIV Modelling Consortium,

2023

The Lancet HIV, (2023).10 4 10.1016/S2352-3018(22)00365-4.